Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
About this item
Full title
Author / Creator
Regula, Jörg T , Lundh von Leithner, Peter , Foxton, Richard , Barathi, Veluchamy A , Cheung, Chui Ming Gemmy , Bo Tun, Sai Bo , Wey, Yeo Sia , Iwata, Daiju , Dostalek, Miroslav , Moelleken, Jörg , Stubenrauch, Kay G , Nogoceke, Everson , Widmer, Gabriella , Strassburger, Pamela , Koss, Michael J , Klein, Christian , Shima, David T and Hartmann, Guido
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Anti‐angiogenic therapies using biological molecules that neutralize vascular endothelial growth factor‐A (VEGF‐A) have revolutionized treatment of retinal vascular diseases including age‐related macular degeneration (AMD). This study reports preclinical assessment of a strategy to enhance anti‐VEGF‐A monotherapy efficacy by targeting both VEGF‐A a...
Alternative Titles
Full title
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
Authors, Artists and Contributors
Author / Creator
Lundh von Leithner, Peter
Foxton, Richard
Barathi, Veluchamy A
Cheung, Chui Ming Gemmy
Bo Tun, Sai Bo
Wey, Yeo Sia
Iwata, Daiju
Dostalek, Miroslav
Moelleken, Jörg
Stubenrauch, Kay G
Nogoceke, Everson
Widmer, Gabriella
Strassburger, Pamela
Koss, Michael J
Klein, Christian
Shima, David T
Hartmann, Guido
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_71a747701bce4cbabf65b970e677ba81
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_71a747701bce4cbabf65b970e677ba81
Other Identifiers
ISSN
1757-4676
E-ISSN
1757-4684
DOI
10.15252/emmm.201505889
